CynapseDx Company

CynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as alzheimer or parkinson disease. They engage in oligomeric and aggregated forms of protein biomarkers and have demonstrated that our assays can measure these forms of biomarker proteins, when testing real patient blood samples.

Funding Status: Seed
Industry: NeuroTech
Investors Number: 1
Last Funding Date: 08-05-2015
Founded Date: 2010
Headquarters: Liverpool, Liverpool, United Kingdom
Last Funding Type: Seed
Employee Number: 1-10